Robert Huffines is an Independent Director of the Company. He joined J.P. Morgan, a leading global financial services firm, in 1991 and currently serves as the Global Chairman of Investment Banking, a position he has held since February 2017. Throughout his career at J.P. Morgan, Mr. Huffines has held various leadership positions, including serving as Co-Head of the Global Healthcare Investment Banking Group from 2002 to 2010 and Vice Chairman from 2011 to January 2017. Mr. Huffines received an M.B.A. from the University of Virginia and a B.A. from the University of North Carolina. Mr. Huffines is qualified to serve on our board of directors based on his over 25 years of experience advising healthcare companies and his leadership experience.
As the Independent Director of Solid Biosciences Inc, the total compensation of Robert Huffines at Solid Biosciences Inc is 74,965$. There are 13 executives at Solid Biosciences Inc getting paid more, with Carl Morris having the highest compensation of 4,052,210$.
Robert Huffines is 55, he's been the Independent Director of Solid Biosciences Inc since 2013. There are 2 older and 19 younger executives at Solid Biosciences Inc. The oldest executive at Solid Biosciences Inc is Stephen J. DiPalma M.B.A., 62, who is the Treasurer & Principal Accounting Officer.
Robert's mailing address filed with the SEC is C/O WALGREENS BOOTS ALLIANCE, INC., 108 WILMOT ROAD, DEERFIELD, IL, 60015.
Over the last 7 years, insiders at Solid Biosciences Inc have traded over 9,620,465$ worth of Solid Biosciences Inc stock and bought 13,973,934 units worth 97,227,521$ . The most active insiders traders include Advisors Llcperceptive Life...、Capital Management, L.P.Ra ...、Rajeev M. Shah. On average, Solid Biosciences Inc executives and independent directors trade stock every 38 days with the average trade being worth of 1,822,871$. The most recent stock trade was executed by Ian F Smith on 3 July 2024, trading 3,255 units of SLDB stock currently worth 24,380$.
solid biosciences (solid) is a cambridge, ma based biotech company singularly focused on developing treatments and cures for duchenne muscular dystrophy (dmd). solid combines sharp commercial focus with world-class science to advance promising therapies and is positioned to catalyze therapeutic development across all aspects of the disease. condition-focused, our mandate is comprehensive; improving daily life for patients and attacking the roots of dmd.
Solid Biosciences Inc executives and other stock owners filed with the SEC include: